This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Effects of testosterone replacement and its pharmacogenetics
on physical performance and metabolism
Michael Zitzmann
Institute of Reproductive Medicine of the University of Münster, Münster D-48129, Germany
Abstract
In men, testosterone (T) deficiency is associated with decreased physical performance, as defined by adverse
traits in body composition, namely increased body fat content and reduced muscle mass. Physical abilities in
androgen-deficient men are further attenuated by lower oxygen supply due to decreased hemoglobin concentrations and by
poor glucose utilization. Dysthymia and a lack of necessary aggressiveness also contribute to deteriorate physical
effectiveness. Substitution of T can improve lipid and insulin metabolism as well as growth of muscle fibers and
decreasing fat depots, which consequently will result in changes of body composition. Increment of bone density will
further contribute to increase physical fitness. The effects of T replacement therapy (TRT) are strongly influenced
by age, training, and also pharmacogenetics: the CAG repeat polymorphism in exon 1 of the androgen receptor (AR)
gene modulates androgen effects. In vitro, transcription of androgen-dependent target genes is attenuated with
increasing length of triplet residues. Clinically, the CAG repeat polymorphism causes significant modulations of
androgenicity in healthy eugonadal men as well as efficacy of TRT. Thresholds at which T treatment should be
initiated, as well as androgen dosage, could be tailored according to this polymorphism.
(Asian J Androl 2008 May; 10: 364_372)
Keywords: testosterone; androgens; hypogonadism; pharmacogenetics; androgen receptor; physical performance; metabolism
Correspondence to: Michael Zitzmann, MD, PhD, Institute of Reproductive Medicine of the University of
Münster, Münster D-48129, Germany.
Tel: +49-251-835604 Fax: +49-251-8356093
E-mail: michael.zitzmann@ukmuenster.de
Received 2007-12-19 Accepted 2007-12-26
DOI: 10.1111/j.1745-7262.2008.00405.x
1 Introduction
Testosterone (T) exerts a widespread pattern of effects on metabolism and body composition. This is most
obviously seen in the difference between men and women. Hypogonadal men lacking sufficient T levels show
evidence of particular physical and metabolic traits seen as alterations in lipid and glucose metabolism, which further
influence fat depots and muscle mass and, ultimately, physical performance. These effects are augmented by adverse
effects of androgen deficiency on hemoglobin levels, bone density, and psychological traits.
T replacement therapy (TRT) in hypogonadal men is able to alter these variables and restore normal male functions.
These effects are reviewed here, starting with the impact of androgens on metabolism and various tissues, and
concluding with a discussion of the effects on psychological and physical performance. New pharmacogenetic
findings are also considered.
2 Pharmacogenetic background
T and its metabolite dihydrotestosterone exert their effects on gene expression and thus affect maleness through
the androgen receptor (AR). A diverse range of clinical conditions, starting with complete androgen insensitivity, has
been correlated with mutations in the AR. Subtle modulations of the transcriptional activity induced by the AR have
also been observed and frequently assigned to a polyglutamine stretch of variable length within the N-terminal domain
of the receptor. This stretch is encoded by a variable number of CAG triplets in exon 1 of the AR gene located on the
X chromosome. Longer triplet residues mitigate binding of AR co-activators and, hence, facilitate decreased
androgenicity. A marked relation to androgenic traits can be seen in men with an elongation of more than 37 CAG
repeats, but also in those with CAG repeats within the normal range [1, 2]. Extending these findings to
pharmacogenetic considerations, a possible modulation of androgen
effects during TRT has to be considered (see below).
3 Metabolic aspects and glucose metabolism
Within the last century, life circumstances have
changed in developed countries as physical activity has
become less frequent and, simultaneously, an
oversupply of food is present. This has resulted in an increasing
prevalence of overweightness and obesity, particularly
over the past two decades. As a consequence, a
complex disorder consisting of visceral obesity, dyslipidemia,
insulin resistance, and hypertension has emerged with
increasing incidence. The so-called "metabolic
syndrome" contributes to a symptomatology that
progressively leads to the manifestation of type 2 diabetes
mellitus and cardiovascular disease. Although the
pathogenesis of the metabolic syndrome and each of its
components is complex and not well understood, central
obesity and insulin resistance are acknowledged as
important causative factors [3_6]. Persons affected are twice
as likely to die from, and three times as likely to suffer, a
heart attack or stroke compared to those free of the
metabolic syndrome [7]. They also have a 5-fold greater
risk of developing type 2 diabetes mellitus, if not already
present [8].
The International Diabetes Federation (IDF) has
recently updated the criteria for diagnosis of the metabolic
syndrome (Reproduced from http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf with
permission from the IDF):
Central obesity, defined as waist circumference
(> 102 cm for North American men, > 94 cm for
European men, and > 90 cm for Asian men), plus any two of
the following four factors:
· Concentrations of fasting triglycerides
> 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid
abnormality
· Concentrations of high-density lipoprotein
cholesterol < 40 mg/dL (1.0 mmol/L) in males, or specific
treatment for this lipid abnormality
· Systolic blood pressure > 130 mmHg or diastolic
blood pressure > 85 mmHg, or treatment of previously
diagnosed hypertension
· Concentrations of fasting plasma glucose
> 100 mg/dL (5.6 mmol/L), or previously diagnosed type
2 diabetes mellitus
In men, obesity as the central component of the
metabolic syndrome is associated with low T concentrations [9_12].
3.1 Epidemiological approaches
A cross-sectional study in independently living men
examined the association between endogenous T concentrations and the prevalence of the metabolic syndrome
as well as relationships between androgen levels and its
sub-components. Logistic regression analyses showed
an inverse relationship for circulating total T
concentrations with the prevalence of the metabolic syndrome.
Within the cohort of men, each increase of one standard
deviation of total T (5.3 nmol/L) was associated with a
57% reduced risk of having the metabolic syndrome. In
agreement, higher T levels were associated with higher
insulin sensitivity. In addition, the more factors of the
metabolic syndrome that were present, the lower the
total T concentrations that were measured [13].
These findings are corroborated by longitudinal
epidemiological approaches. In a cohort of 700 healthy
middle-aged Finnish men without metabolic syndrome,
concentrations of total T and factors related to insulin
resistance were determined at baseline and after 11 years.
During that time, 147 men had developed the metabolic
syndrome. Men with total T in the lower fourth quartile
had an increased risk of developing the disorder and
subsequent type 2 diabetes mellitus. Adjustment for
potential confounders such as cardiovascular disease, smoking,
alcohol intake, and socioeconomic status did not alter
the associations [14]. A similar approach was taken in
950 healthy, aging men during the Massachusetts Male
Aging Study. The incidence of the metabolic syndrome
was strongly related to lower T concentrations,
especially in men with a body mass index (BMI) lower than
25 kg/m2. This points to the specific, adverse role of
central adiposity in combination with androgen deficiency, especially in those men with slender
extremities compared to generally overweight persons. The
latter develop the metabolic syndrome more independently
from androgen deficiency [15].
Summarizing these non-interventional findings, there
are strong indications that a T deficiency in men might
contribute to the prevalence of the metabolic syndrome.
This applies especially to elderly persons with an
age-related decline of hypothalamic_pituitary_testicular
functionality, referred to as late-onset hypogonadism [16,
17]. Nevertheless, non-interventional studies cannot fully
elucidate cause and effect in this regard: the metabolic
syndrome leading to vascular and endocrine disturbances
might initiate hypogonadism as well, an effect known
from other chronic disorders [18]. There are
indications that such an effect exists, as a Finnish cohort study
involving 651 men indicated. After 11 years of surveillance, the odds ratio was 3 to be diagnosed with
total T concentrations below 11 nmol/L for men with
the metabolic syndrome compared to non-affected persons
[19].
3.2 Interventional studies
Interventional approaches altering T concentrations
are able to further illuminate these questions.
Pharmacological deprivation of T is a treatment option in men with
prostate cancer. A study in such patients assessed the
effects of short-term gonadotropin-releasing hormone
(GnRH) agonist treatment on insulin sensitivity within the
setting of a prospective 12-week study involving 25 men
without evidence of diabetes mellitus at baseline.
Leuprolide depot and bicalutamide were used for T ablation. The mean percentage of body fat mass as well
as mean hemoglobin type A1c (HbA1c) increased
significantly, whereas insulin sensitivity decreased markedly
[20].
The results are corroborated by a cross-sectional
study in 53 men, including 18 men with prostate
carcinoma, who received androgen ablation for at least 12 months
prior to the onset of the study, 17 age-matched men with
non-metastatic prostate carcinoma who had undergone
prostatectomy and/or received radiotherapy and who
were not receiving androgen ablation therapy, and 18
age-matched controls. None of the men had a known
history of diabetes mellitus. Men in the treatment group
had a higher BMI compared with the other groups as
well as higher fasting levels of glucose, insulin, and leptin.
The homeostatic model assessment for insulin resistance
showed markedly higher values for men with decreased
T concentrations [21].
Consistently, a placebo-controlled study in healthy
men receiving short-term T deprivation by a
GnRH-receptor antagonist showed incremental effects on
concentrations of insulin and leptin after 3 weeks within a
condition of marked hypogonadism [22].
Correspondingly, androgen substitution in
hypogo-nadal men has marked beneficial effects on these
metabolic markers. In a well designed double-blind study, 30
middle-aged men with abdominal obesity were treated
with transdermal preparations of T, dihydrotestosterone,
or placebo. In the group treated with T, visceral fat
mass decreased (measured by computerized tomography)
without significant changes in other depot fat regions.
In addition, the glucose disposal rate, measured with a
euglycemic hyperinsulinemic clamp, was markedly augmented. Plasma triglycerides, cholesterol, and
fasting blood glucose concentrations, as well as diastolic blood
pressure, decreased [23].
Corresponding effects were seen in 24 hypogonadal
men with type 2 diabetes mellitus involved in a
double-blind placebo-controlled crossover study. The men
received an intramuscular T preparation or placebo for
3 months in random order, followed by a washout
period of 1 month before the alternate treatment phase.
T therapy improved fasting insulin sensitivity. HbA1c
levels were reduced correspondingly, as were fasting
blood glucose levels. T treatment resulted in a reduction
in visceral adiposity as assessed by waist circumference.
Total cholesterol decreased with T therapy but no effect
on blood pressure was observed [24].
These studies are supported by a larger,
cross-sectional observation in elderly men. The subjects were
either untreated hypogonadal men (n = 24), treated
hypogonadal men (n = 61), or healthy eugonadal men
(n = 60). In eugonadal men, serum T levels decreased
with advancing age while BMI, total body fat content,
and leptin increased significantly. In untreated hypogonadal patients, an increase in BMI and total fat
mass was also observed with advancing age. However,
in substituted hypogonadal patients, no age-dependent
change in BMI, body fat content, or serum leptin was
found [25]. The decreasing effects of T treatment on
visceral adipose tissue are most likely dose-dependent,
as shown by a study in men receiving various doses of
intramuscular T [26].
3.3 Pathophysiological considerations
Visceral fat tissue plays a central role within the
metabolic syndrome, acting as a source of inflammatory,
anti-insulinergic, and atherogenically relevant cytokines such
as tumor necrosis factor-α and interleukin-6 [27, 28].
Fat tissue also functions as an endocrine organ, its
product adiponectin plays an important role in metabolism
and is related to cardiovascular risk factors. It is
produced by fat cells in large quantities, yet its levels are
inversely associated with total body fat mass, most likely
caused by auto/paracrine downregulation through
inflammatory cytokines. Improvement of insulin sensitivity
and inhibition of various atherogenic processes within
the vessel wall are direct effects of adiponectin [29].
Leptin is another hormone secreted by fat cells. Hypophagia to reduce fat mass is supported by leptin
signals, but adipose tissue fosters further food intake by
facilitating leptin resistance at the hypothalamic level by
way of afferent nerve signals [30]. A vicious circle is
thus induced as leptin resistance increases further
adipocyte-related production of this hormone. There are
indications that high levels of leptin can mitigate T
secretion [31, 32].
T seems to have various effects on fat cells and
insulin resistance. A study in mouse pluripotent stem cells
indicates that T regulates body composition by
promoting the commitment of these mesenchymal cells into the
myogenic lineage and inhibiting their differentiation into
the adipogenic lineage. This provides a unifying
explanation for the reciprocal effects of androgens on muscle
and fat mass in men [33]. An inhibiting effect of T has
also been described concerning the differentiation of
pre-adipocytes. In 3T3-L1 cells that differentiate to form fat
cells in adipogenic medium, T inhibits adipocyte
differentiation in vitro through an AR-mediated nuclear
translocation of β-catenin and activation of downstream Wnt
signaling (such Wnt signals direct distinct fates of
differentiation in precursor cell types) [34]. In addition, T
increases lipolysis and the number of adrenoreceptors in
male rat adipocytes [35].
T might facilitate insulin sensitivity both in fat and
muscle cells by upregulating the expression of
insulin-induced downstream protein expression. Respective
dose-dependent effects of T on insulin receptor substrate-1
and glucose transporter 4 expression were seen in cell
models [36]. Recent models of insulin resistance also
suggest a pivotal role of mitochondrial function with the
decreased transcription of oxidative phosphorylation
genes in skeletal muscle of insulin-resistant subjects. This
leads to decreased oxidative phosphorylation, decreased
lipid oxidation, intracellular accumulation of triglycerides
in skeletal muscle, and ultimately insulin resistance [37].
A study in 60 men showed T levels to correlate
positively with mitochondrial capacity assessed by
measuring maximal aerobic capacity and also expression of
oxidative phosphorylation genes [38].
As discussed, leptin resistance and consequently
upregulated adipocyte leptin secretion play a pivotal role
in obesity. T substitution in hypogonadal men is able to
reduce leptin secretion of fat cells, probably by an
AR-mediated pathway [12], thus breaking the described
vicious circle of leptin resistance and obesity [25, 39_41].
3.4 Role of AR in metabolism
T effects are mediated by the AR [42]. It is
therefore not surprising that an AR knock-out model in mice
shows evidence of effects in agreement with T deficiency.
Progressively reduced insulin sensitivity and impaired
glucose tolerance are seen these mice with advancing age.
Aging AR knock-out mice have accelerated weight gain,
hyperinsulinemia, and hyperglycemia. The loss of the
AR contributes to increased triglyceride content in
skeletal muscle and liver in these animals and leptin
concentrations are elevated in serum [43].
Apart from complete dysfunctionality of the AR,
modulations of its activity have been observed and can
be assigned to a polymorphic polyglutamine stretch of
variable length within the N-terminal domain of the
receptor protein. This stretch is encoded by a variable
number of CAG triplets in exon 1 of the AR gene,
located on the X chromosome. The length of the
polymorphism is inversely associated with androgen-induced
gene transcription [41]. Pathological CAG triplet
elongations (> 36) are observed in spinobulbar muscular
atrophy, the so-called "Kennedy syndrome". Long
before the AR polymorphism was recognized as a cause
for the disease [44], an association of the disorder with
diabetes mellitus had been suspected [45]. As confirmed
recently, markedly reduced androgen function indeed
leads to pathological glucose metabolism in approximately
50% of these patients [46]. Also within the normal range
of CAG triplet length (13_36 repeats), modulatory
effects on androgenic activity are reflected by metabolic
parameters. Concentrations of insulin and leptin as well
as body composition in men are associated with this
polymorphism [12, 47].
3.5 Metabolic perspectives for men
Hypogonadal men, especially Klinefelter patients,
have an increased prevalence of the metabolic syndrome
[48]. Special efforts to detect this under-diagnosed
chromosome disorder and mitigate the increased mortality of these men due to complications of diabetes
mellitus and cardiovascular events [49] are necessary.
Although approaches examining the effects of T on
sub-parameters of the metabolic syndrome have been made
(see above), prospective studies investigating its incidence
in hypogonadal men receiving T substitution therapy are
needed. Such studies should take the modulatory effect
of the AR into account to fully elucidate the putative
potential of T to attenuate or prevent the metabolic
syndrome in men.
4 Erythropoeisis
T treatment for anemia in patients with renal failure
was a common medication before synthetic erythropoetin
was available [50]. T probably acts directly on bone
marrow at the level of polychromatophylic erythroblasts
and enhances the synthesis of ribosomal RNA or its
precursors and stimulates a nuclear ribonuclease. It was
postulated that erythropoietin and T act synergistically to
create the biochemical machinery for hemoglobin
synthesis [51]. In agreement, hypogonadal men often present
with anemia. Elevation of T levels, irrespective of the
preparation used, will increase hemoglobin levels in these
patients [52_54]. Substitution effects will reach a
plateau after approximately 6_9 months [56]. The
above-mentioned studies show a marked variability in
responsiveness of the hematopoetic system to T and strengthen
the necessity for surveillance. In some men,
unacceptably high levels of hemoglobin concentration and
hematocrit can develop, so that the dosage has to be
adjusted in order to prevent adverse vascular events [52].
It has been shown that pharmacogenetic effects of the
CAG repeat polymorphism are visible during TRT and
have to be considered for evaluating erythropoeisis and
hematocrit [57].
5 Body composition
5.1 Body fat content
Cross-sectional investigations in healthy, eugonadal
men have indicated a negative relationship between body
fat content and levels of total T [58, 59], this applies in
particular to abdominal fat tissue [9, 11]. In healthy obese
men, the issue is complicated by simultaneously
decreasing levels of sex hormone binding globulin, thus levels of
free or bioavailable T are often maintained [60].
In hypogonadal men, an increased total BMI is
regularly observed as well as a reduced lean body mass,
measured with dual photon absorptiometry (DEXA) or
bioimpedance, is found when compared to age-matched
healthy controls, suggesting higher body weight due to
increased fat mass in the presence of lower muscle mass
[61, 62]. T treatment can significantly reduce body fat
content in hypogonadal men and, vice versa, it can
increase lean body mass, an observation that is not only
due to shifts in proportions but also to growth of muscle
tissue (see below) [25, 52, 53, 63_67]. This is exerted
through a redistribution of body fat during which mainly
visceral and intermuscular fat depots are affected, but
subcutaneous tissue seems to be spared [68]; it is likely
that fat cell size itself is modulated by androgens [69].
The process seems to follow a linear dose_response
relationship to T [68], but the exact mechanism by which
fat cells are subject to androgen influence is not known.
It can be speculated that this is mediated through
increased insulin sensitity and improved glucose utilization,
resulting in lower insulin levels and, thus, less lipid storage.
5.2 Muscle tissue
In addition to the effects of T deficiency on body fat
content, a loss of fat-free mass and decrease in muscle
protein synthesis is observed in hypogonadal men [70].
In agreement with these findings, when androgens are
substituted in such patients, fat-free mass increases
significantly, an effect attributable to muscle growth [65,
71]. The growth of muscle tissue seems to follow a
linear dose_response relationship over a wide range of T
levels, as was indicated in healthy young men receiving
androgen ablation by a GnRH agonist and subsequent T
treatment in various doses to achieve low to
supraphy-siological levels. As fat-free mass increased with the
increasing T dose, so did volumes of thigh muscles [72].
Muscle biopsies in these men indicated a homogenous
increase in cross-sectional areas of both type I and II
muscle fibers, which maintained their proportion. As
muscle fiber hypertrophy involves the addition of newly
formed myonuclei through the fusion of myogenic cells,
the myonuclear number increased in direct
relation to the increase in muscle fiber diameter. Muscle cell
hyperplasia did not play a significant role [73].
5.3 Bone tissue
In conditions of T deficiency, bone mineral density is decreased and markers of bone turnover are
usually elevated [74_77]. Especially in hypogonadal
men, whose trabecular bone density is decreased, T
substitution is effective in regard to significant increase
in bone density, particularly in those patients with a
marked baseline deficit [78_82]. The type of hormone substitution as well as the disease causing low
androgen levels do not influence the effectiveness of T
substitution on bone density. Nevertheless, there is a
tendency of higher T substitution levels to contribute
to higher bone density, albeit marginally, as androgen
influence on bone tissue seems to be non-linear. The
effect is much stronger in alterations within the low
range than in the high range and is influenced by the
CAG repeat polymorphism [83].
The underlying mechanisms depend on both T and estradiol, as they contribute to higher bone density. These
effects are probably exerted through different pathways:
T inhibits osteoclastic activity, whereas estradiol seems
to activate osteoblasts [84, 85]. As an interactive,
paracrine positive feedback exists between both types of
cells [86], both hormones take effect on both types of
cells. The mediators of these effects are still unclear.
Indications are that androgens act mainly through
inhibition of secretion of the cytokine interleukin-6, thus
downregulating osteoclastic activity [87, 88], but also
through the insulin-like growth factor system of
osteoblasts [89]. T treatment given externally leads to
reduction of markers of bone turnover [87]. It is possible that
increased muscle strength during T substitution
contributes to the gain of bone tissue by enhancing traction
forces, a positive stimulus for osteoblasts [90].
6 Mental issues
Physical performance is strongly influenced by mental
status. Mood changes in terms of depression and
aggression are especially likely to modulate physical abilities.
Both parameters are subject to androgen influence and
an interdepence of physical performance with both
hormone levels and mood is likely to exist [91].
6.1 Depressiveness
A relation between T levels and depressive mood
disorders has been shown by investigations in patients treated
for major depression [92, 93]. Viewing the aspect from
the angle of hypogonadism, clinical consensus exists that
this condition in men is related to depressive symptoms.
Low T levels seem to be associated with depressive
symptoms and late-life dysthymia [94]. When T levels and
depressive symptoms were collected in a large sample of
elderly men (n = 856; mean age 70.2 ± 9.2 years), Beck
Depression Inventory scores and free T levels were
inversely correlated with high significance [95].
In a large sample of healthy older men, T levels and
modulation of androgen activity by the CAG repeat
polymorphism of the AR gene are associated with depressed
mood [96]. Therefore, it is no surprise that hypogonadal
men profit largely from T substitution in regard of mood
improvement, an effect that seems to be independent
from substitution modalities [52, 97, 98].
6.2 Aggression
Indications are strong that there is an interdependent
feedback mechanism between T and aggression that is
modified by experiences of victory and defeat, as well as
by education, cultural, and socioeconomic background
[99]. The immense variety of individual response
patterns to androgens was shown by a controlled trial in which
exceptionally high doses of 600 mg
T-cypionate/week were given. Aggressive effects were reported in 16% of the
men. The psychological behavior of the others remained
unremarkable [100]. The effects of T treatment, given
externally, on aggressive behaviour in eugonadal men are
seen as controversial [101_103].
In hypogonadal men, several sub-parameters
associated with aggression such as tension, anger, and
fatigue can be reduced by T substitution and,
simulta-neously, vigor can increase. There is obviously a level
of negative affect experienced by hypogonadal men that
can be reduced by elevation of androgen levels [104].
7 Physical performance
As outlined above, hypogonadism is associated with
increased body fat content, reduced muscle mass,
unfavorable parameters of glucose metabolism, anemia, and
mood disorders. One can therefore assume that actual
physical performance is reduced in these patients and
can possibly be restored by elevation of T levels.
Nevertheless, it is important to distinguish between
various kinds of physical effort.
7.1 Strength
Physical strength, as determined by the
one-repetitive maximum in bench press and seated leg press
exercises (this assesses the maximal
force-generating capacity of the muscles used to perform the test), can
improve in hypogonadal men when T levels are artificially
elevated [52, 66]. Such results are dependent on the
muscle. Larger thigh muscles in particular show a
measurable response, whereas the effects in smaller
shoulder muscles are not significant [54, 55]. Variation in
results can also be explained by different settings (training
or no training) and the age of patients. It seems that gain
of strength by T substitution is possible without training
in younger men [72] but this is not achievable to a
significant degree in older persons, despite an increase in
muscle mass [105]. A significant dose_response
relationship of gained strength and the amount of
substituted T seems to exist, reaching a putative plateau at the
supraphysiological range of T concentrations, despite a
further growth of muscle tissue [72].
7.2 Endurance, gait, balance and mobility
One could expect an overall improvement of the above-named variables when T levels are elevated in
hypogonadal men, as these parameters depend on muscle
mass, body composition in general, hemoglobin content
as oxygen provider, as well as mood, all being improved
by androgen substitution. Nevertheless, data
strengthening such hypotheses are scarce. An increased number
of red blood cells improving oxygen supply is likely to
improve endurance capacities, as has been seen in trials
with rats treated with nandrolone [106] or reports
concerning athletes using uncontrolled doping [107].
In hypogonadal men, the fractional velocity of muscle
glycogen synthetase can be increased by T treatment
[108]. Along with improved oxygen supply, this could
infer increased performance in efforts requiring
endurance rather than strength.
Gait, balance and mobility under treatment with a
dihydrotestosterone gel were tested in a controlled setting
involving 31 older men with low to low-normal T levels.
Despite significant positive changes in lean body mass,
strength, and hemoglobin content, the complex variables
assessed by maximal reach, standing balance, fast walk,
or chair rise were not altered by treatment [55].
8 Conclusion
Hypogonadism in men is a state associated with
decreased physical abilities, especially strength and
endurance. These endpoints are based on significantly
measurable adverse traits in body composition, namely
increased fat content and reduced muscle mass.
Physical abilities are further hampered by lower oxygen
supply due to decreased hemoglobin levels and poor glucose
utilization. In addition, dysthymia and lack of necessary
aggressiveness contribute to further deteriorate physical
performance.
Substitution of T can improve lipid and insulin
metabolism, which consequently results in changes of
body composition, such as decreasing fat depots and
growing muscle fibers. Stabilization by increased bone
density will further contribute to performance. This is
ultimately reflected by increased strength, although this
parameter is subject to various other influences, such as
age and training. The reviewed issues strongly support
treatment of hypogonadal men under regular monitoring.
The effects of T are most likely modulated by the CAG
repeat AR polymorphism. An indiviually tailored approach
to T treatment is a future option.
References
1 Canale D, Caglieresi C, Moschini C, Liberati CD, Macchia E,
Pinchera A, et al. Androgen receptor polymorphism (CAG repeats)
and androgenicity. Clin Endocrinol (Oxf) 2005; 63: 356_61.
2 Zitzmann M. Mechanisms of disease: pharmacogenetics of
testosterone therapy in hypogonadal men. Nat Clin Pract Urol
2007; 4: 161_6.
3 Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS,
Thomas GN, et al. Factor analysis of the metabolic syndrome:
obesity vs insulin resistance as the central abnormality. Int J
Obesity 2001; 25: 1782_8.
4 Eisenmann JC. Secular trends in variables associated with the
metabolic syndrome of North American children and adolescents:
a review and synthesis. Am J Hum Biol 2003; 15: 786_94.
5 Carr DB, Utzschneider KM, Hull RL. Intra-abdominal fat is a
major determinant of the National Cholesterol Education
Program Adult Treatment Panel III criteria for the metabolic
syndrome. Diabetes 2004; 53: 2087_94.
6 Cassells HB, Haffner SM. The metabolic syndrome: risk factors
and management. J Cardiovasc Nurs 2006; 21: 306_13.
7 Isomaa B, Almgren P, Tuomi T. Cardiovascular morbidity and
mortality associated with the metabolic syndrome. Diabetes
Care 2001; 24: 683_9.
8 Stern M, Williams K, Gonzalez-Villalpando C. Does the
metabolic syndrome improve identification of individuals at risk of
type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;
27: 2676_81.
9 Khaw KT, Barrett-Connor E. Lower endogenous androgens
predict central adiposity in men. Ann Epidemiol 1992; 2: 675_82.
10 van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts
SW. Measures of bioavailable serum testosterone and estradiol
and their relationships with muscle strength, bone density, and
body composition in elderly men. J Clin Endocrinol Metab
2000; 85: 3276_82.
11 Marin P, Arver S. Androgens and abdominal obesity. Baillieres
Clin Endocrinol Metab 1998; 12: 441_51.
12 Zitzmann M, Gromoll J, von Eckardstein A, Nieschlag E. The
CAG repeat polymorphism in the androgen receptor gene
modulates body fat mass and serum concentrations of leptin and
insulin in men. Diabetologia 2003; 46: 31_9.
13 Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der
Schouw YT. Endogenous sex hormones and metabolic syndrome
in aging men. J Clin Endocrinol Metab 2005; 90: 2618_23.
14 Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K,
Tuomainen TP, Valkonen VP, et al. Testosterone and sex
hormone-binding globulin predict the metabolic syndrome and
diabetes in middle-aged men. Diabetes Care 2004; 27: 1036_41.
15 Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ,
McKinlay JB. Low sex hormone-binding globulin, total testosterone,
and symptomatic androgen deficiency are associated with
development of the metabolic syndrome in nonobese men. J Clin Endocrinol
Metab 2006; 91: 843_50.
16 Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM,
Legros JJ, et al. Investigation, treatment and monitoring of
late-onset hypogonadism in males: ISA, ISSAM, and EAU
recommendations. Int J Androl 2005; 28: 125_7.
17 Zitzmann M, Nieschlag E. Testosterone substitution: current
modalities and perspectives. J Reprod Med Endocrinol 2006; 3:
109_16.
18 Liu P, Handelsman DJ. Androgens and erythropoiesis. In:
Nieschlag E, Behre HM, editors. Testosterone_Action, Deficiency,
Substitution, 3rd edn. Cambridge: Cambridge University Press;
2004. p283_96.
19 Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K,
Tuomainen TP, Valkonen VP, et al. The metabolic syndrome
and smoking in relation to hypogonadism in middle-aged men: a
prospective cohort study. J Clin Endocrinol Metab 2005; 90:
712_9.
20 Smith MR, Lee H, Nathan DM. Insulin sensitivity during
combined androgen blockade for prostate cancer. J Clin Endocrinol
Metab 2006; 91: 1305_8.
21 Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS.
Hyperglycemia and insulin resistance in men with prostate carcinoma who
receive androgen-deprivation therapy. Cancer 2006; 106: 581_8.
22 Büchter D, Behre HM, Kliesch S, Chirazi A, Nieschlag E, Assmann
G, et al. Effects of testosterone suppression in young men by the
gonadotropin releasing hormone antagonist cetrorelix on plasma
lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin.
Exp Clin Endocrinol Diabetes 1999; 107: 522_9.
23 Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander
A, et al. Androgen treatment of abdominally obese men. Obes
Res 1993; 1: 245_51.
24 Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone
replacement therapy improves insulin resistance, glycaemic
control, visceral adiposity and hypercholesterolaemia in
hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;
154: 899_906.
25 Rolf C, von Eckardstein S, Koken U, Nieschlag E. Testosterone
substitution of hypogonadal men prevents the age-dependent
increases in body mass index, body fat and leptin seen in healthy
ageing men: results of a cross-sectional study. Eur J Endocrinol
2002; 146: 505_11.
26 Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J,
et al. Dose-dependent effects of testosterone on regional adipose
tissue distribution in healthy young men. J Clin Endocrinol
Metab 2004; 89: 718_26.
27 Grimble RF. Inflammatory status and insulin resistance. Curr
Opin Clin Nutr Metab Care 2002; 5: 551_9.
28 Guerre-Millo M. Adipose tissue hormones. J Endocrinol Invest
2002; 25: 855_61.
29 Diez JJ, Iglesias P. The role of the novel adipocyte-derived
hormone adiponectin in human disease. Eur J Endocrinol 2003; 148:
293_300.
30 Yamada T, Katagiri H, Ishigaki Y, Ogihara T, Imai J, Uno K,
et al. Signals from intra-abdominal fat modulate insulin and leptin
sensitivity through different mechanisms: neuronal involvement in
food-intake regulation. Cell Metab 2006; 3: 223_9.
31 Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A,
et al. Leptin and androgens in male obesity: evidence for leptin
contribution to reduced androgen levels. J Clin Endocrinol Metab
1999; 84: 3673_80.
32 Isidori AM, Strollo F, More M, Caprio M, Aversa A, Moretti C,
et al. Leptin and aging: correlation with endocrine changes in
male and female healthy adult populations of different body
weights. J Clin Endocrinol Metab 2000; 85: 1954_62.
33 Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S.
Androgens stimulate myogenic differentiation and inhibit
adipogenesis in C3H 10T1/2 pluripotent cells through an androgen
receptor-mediated pathway. Endocrinology 2003;144:5081_8.
34 Singh R, Artaza JN, Taylor WE, Braga M, Yuan X,
Gonzalez-Cadavid NF, et al. Testosterone inhibits adipogenic
differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor
complex with beta-catenin and T-cell factor 4 may bypass
canonical Wnt signaling to down-regulate adipogenic transcription
factors. Endocrinology 2006; 147: 141_54.
35 Xu XF, De Pergola G, Björntorp P. Testosterone increases
lipolysis and the number of beta-adrenoreceptors in male rat
adipocytes. Endocrinology 1991; 128: 379_82.
36 Chen X, Li X, Huang HY, Li X, Lin JF. [Effects of testosterone
on insulin receptor substrate-1 and glucose transporter 4
expression in cells sensitive to insulin.] Zhonghua Yi Xue Za Zhi 2006;
86: 1474_7. Chinese.
37 Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S,
Lehar J, et al. PGC-1alpha-responsive genes involved in
oxidative phosphorylation are coordinately downregulated in human
diabetes. Nat Genet 2003; 34: 267_73.
38 Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson
KF, et al. Relationship between testosterone levels, insulin
sensitivity, and mitochondrial function in men. Diabetes Care
2005; 28: 1636_42.
39 Behre HM, Simoni M, Nieschlag E. Strong association between
serum levels of leptin and testosterone in men. Clin Endocrinol
(Oxf) 1997; 47: 237_40.
40 Jockenhövel F, Blum WF, Vogel E, Englaro P, Muller-Wieland
D, Reinwein D, et al. Testosterone substitution normalizes
elevated serum leptin levels in hypogonadal men. J Clin Endocrinol
Metab 1997; 82: 2510_13.
41 Mayes JS, Watson GH. Direct effects of sex steroid hormones on
adipose tissues and obesity. Obes Rev 2004; 5: 197_216.
42 Hiort O, Zitzmann M. Androgen receptor pathophysiology. In:
Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency,
Substitution, 3rd edn. Cambridge: Cambridge University Press;
2004. p93_124.
43 Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C. Insulin and
leptin resistance with hyperleptinemia in mice lacking androgen
receptor. Diabetes 2005; 54: 1717_25.
44 La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck
KH. Androgen receptor gene mutations in X-linked spinal and
bulbar muscular atrophy. Nature 1991; 352: 77_9.
45 Cazzola R, Giovannini A. Diabetes mellitus during the course of
familial progressive muscular atrophy; incidental association or
metabolic manifestation of the myopathy? Arch Patol Clin Med
1957; 34: 335_42.
46 Sinnreich M, Sorenson EJ, Klein CJ. Neurologic course,
endocrine dysfunction and triplet repeat size in spinal bulbar muscular
atrophy. Can J Neurol Sci 2004; 31: 378_82.
47 Walsh S, Zmuda JM, Cauley JA, Shea PR, Metter EJ, Hurley BF,
et al. Androgen receptor CAG repeat polymorphism is
associated with fat-free mass in men. J Appl Physiol 2005; 98: 132_7.
48 Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L,
Bennett P, et al. The metabolic syndrome is frequent in
Klinefelter's syndrome and is associated with abdominal obesity
and hypogonadism. Diabetes Care 2006; 29: 1591_8.
49 Bojesen A, Juul S, Birkebaek NH, Gravholt CH. Morbidity in
Klinefelter syndrome: a Danish register study based on hospital
discharge diagnoses. J Clin Endocrinol Metab 2006; 91: 1254_60.
50 von Hartitzsch B, Kerr DN, Morley G, Marks B. Androgens in
the anaemia of chronic renal failure. Nephron 1977; 18: 13_20.
51 Perretta M, Valladares L, Romero C, Sierralta W, Valenzuela A,
Spencer E, et al. Hormone action on the cell nucleus: effect of
erythropoietin and testosterone on bone marrow. Arch Biol
Med Exp 1976; 10: 35_40.
52 Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ,
Cunningham G, et al. Transdermal testosterone gel improves
sexual function, mood, muscle strength, and body composition
parameters in hypogonadal men. Testosterone Gel Study Group.
J Clin Endocrinol Metab 2000; 85: 2839_53.
53 Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C.
Testosterone replacement in older hypogonadal men: a 12-month
randomized controlled trial. J Clin Endocrinol Metab 1997; 82:
1661_7.
54 Liu PY, Wishart SM, Handelsman DJ. A double-blind,
placebo-controlled, randomized clinical trial of recombinant human
chorionic gonadotropin on muscle strength and physical function and
activity in older men with partial age-related androgen deficiency.
J Clin Endocrinol Metab 2002; 87: 3125_35.
55 Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ,
Handelsman DJ. A double-blind, placebo-controlled, randomized
clinical trial of transdermal dihydrotestosterone gel on muscular
strength, mobility, and quality of life in older men with partial
androgen deficiency. J Clin Endocrinol Metab 2001; 86: 4078_88.
56 Von Eckardstein S, Nieschlag E. Treatment of male
hypogonadism with testosterone undecanoate injected at extended
intervals of 12 weeks: a phase II study. J Androl 2002; 23: 419_25.
57 Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat
length and body mass index modulate the safety of long-term
intramuscular testosterone undecanoate therapy in hypogonadal
men. J Clin Endocrinol Metab 2007; 92: 3844_53.
58 Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body
composition and aging. J Endocrinol Invest 1999; 22: 110_16.
59 Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V,
et al. Association between plasma total testosterone and
cardiovascular risk factors in healthy adult men: the Telecom Study. J
Clin Endocrinol Metab 1997; 82: 682_5.
60 Vermeulen A, Kaufman JM, Giagulli VA. Influence of some
biological indexes on sex hormone-binding globulin and androgen
levels in aging or obese males. J Clin Endocrinol Metab 1996;
81: 1821_6.
61 Marin P. Testosterone and regional fat distribution. Obes Res
1995; 3 (Suppl 4): 609_12.
62 Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI,
Anderson EJ, Klibanski A. Increase in bone density and lean body mass
during testosterone administration in men with acquired
hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358_65.
63 Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of
middle-aged, obese men: effects on metabolism, muscle and
adipose tissues. Eur J Med 1992; 1: 329_36.
64 Behre HM, von Eckardstein S, Kliesch S, Nieschlag E. Long-term
substitution therapy of hypogonadal men with transscrotal
testosterone over 7_10 years. Clin Endocrinol 1999; 50: 629_35.
65 Bhasin S, Storer TW, Berman N, Yarasheski KE, Cleveneger B,
Casaburi RA. A replacement dose of testosterone increases
fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol
Metab 1997; 82: 407_13.
66 Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati
A, et al. Effects of testosterone replacement in hypogonadal
men. J Clin Endocrinol Metab 2000; 85: 2670_7.
67 Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI.
Testosterone therapy prevents gain in visceral adipose tissue and
loss of skeletal muscle in nonobese aging men. J Clin Endocrinol
Metab 2008; 93: 139_46.
68 Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J,
et al. Dose-dependent effects of testosterone on regional
adipose tissue distribution in healthy young men. J Clin Endocrinol
Metab 2004; 89: 718_26.
69 Garaulet M, Perex-Llamas F, Fuente T, Zamora S, Tebar FJ.
Anthropometric, computed tomography and fat cell data in an
obese population: relationship with insulin, leptin, tumor
necrosis factor-alpha, sex hormone-binding globulin and sex hormones.
Eur J Endocrinol 2000; 143: 657_66.
70 Mauras N, Hayes V, Welch S, Veldhuis J, Urban R. Testosterone
deficiency in young men: marked alterations in whole body
protein kinetics, strength, and adiposity. J Clin Endocrinol Metab
1998; 83: 1886_92.
71 Brodsky IG, Balagopal P, Nair KS. Effects of testosterone
replacement on muscle mass and muscle protein synthesis in
hypogonadal men_a clinical research center study. J Clin
Endocrinol Metab 1996; 81: 3469_75.
72 Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman
N, et al. Testosterone dose_response relationships in healthy young
men. Am J Physiol Endocrinol Metab 2001; 281: E1172_81.
73 Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh
AB, Lee MI, et al. Testosterone-induced increase in muscle size in
healthy young men is associated with muscle fiber hypertrophy.
Am J Physiol Endocrinol Metab 2002; 283: E154_64.
74 Fukuda S, Iida H. Effects of orchidectomy on bone metabolism
in beagle dogs. J Vet Med Sci 2000; 62: 69_73.
75 Scopacasa F, Horowitz M, Wishart JM, Morris HA, Chatterton
BE, Need AG. The relation between bone density, free androgen
index, and estradiol in men 60 to 70 years old. Bone 2000; 27:
145_9.
76 Erben RG, Eberle J, Stahr K, Goldberg M. Androgen deficiency
induces high turnover osteopenia in aged male rats: a sequential
histomorphometric study. J Bone Miner Res 2000; 15:
1085_98.
77 Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ.
Castrated men exhibit bone loss: effect of calcitonin treatment
on biochemical indices of bone remodeling. J Clin Endocrinol
Metab 1989; 69: 523_7.
78 Leifke E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag
E. Effects of testosterone replacement therapy on cortical and
trabecular bone mineral density, vertebral body area and paraspinal
muscle area in hypogonadal men. Eur J Endocrinol 1998; 138:
51_8.
79 Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E.
Long-term effect of testosterone therapy on bone mineral density in
hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386_90.
80 Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes
JH, et al. Effect of testosterone treatment on bone mineral
density in men over 65 years of age. J Clin Endocrinol Metab
1999; 84: 1966_72.
81 Wang C, Swerdloff RS, Iranmanesh A. Effects of transdermal T
gel on bone turnover markers and bone mineral density in
hypogonadal men. Clin Endocrinol (Oxf) 2001; 54: 739_50.
82 Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz
LG. Effects of transdermal T on bone and muscle in older men
with low bioavailable T levels. J Gerontol A Biol Sci Med Sci
2001; 56: M266_72.
83 Zitzmann M, Brune M, Vieth V, Nieschlag E. Monitoring bone
density in hypogonadal men with phalangeal ultrasound. Bone
2002; 31: 422_9.
84 Damien E, Price JS, Lanyon LE. Mechanical strain stimulates
osteoblast proliferation through the estrogen receptor in males
as well as females. J Bone Miner Res 2000; 15: 2169_77.
85 Fohr B, Schulz A, Battmann A. Sex steroids and bone metabolism:
comparison of in vitro effects of 17β-estradiol and testosterone on
human osteosarcoma cell lines of various gender and differentiation.
Exp Clin Endocrinol Diabetes 2000; 108: 414_23.
86 Ziegler R. Der Knochen und seine Erkrankungen, Teil II. Deutsche
Medizinische Wochenschrift 1995; 120: 571_2.
87 Finkelstein JS. Androgens and bone metabolism. In: Nieschlag
E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution.
Berlin and New York: Springer; 1998. 187_208.
88 Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H,
Dalrymple SA, et al. Regulation of
interleukin-6, osteoclasto-genesis, and bone mass by androgens. The role of the androgen
receptor. J Clin Invest 1995; 95: 2886_95.
89 Gori F, Hofbauer LC, Conover CA, Khosla S. Effects of
androgens on the insulin-like growth factor system in an
androgen-responsive human osteoblastic cell line. Endocrinology 1999;
140: 5579_86.
90 Aparicio LF, Jurkovic M, DeLullo J. Decreased bone density in
ambulatory patients with duchenne muscular dystrophy. J Pediatr
Orthop 2002; 22: 179_81.
91 Filaire E, Bernain X, Sagnol M, Lac G. Preliminary results on
mood state, salivary testosterone:cortisol ratio and team
performance in a professional soccer team. Eur J Appl Physiol 2001;
86: 179_84.
92 Schweiger U, Deuschle M, Weber B, Korner A, Lammers CH,
Schmider J, et al. Testosterone gonadotropin and cortisol
secretion in male patients with major depression. Psychosom Med
1999; 61: 292_6.
93 Unden F, Ljunggren JG, Beck-Friis J, Kjellman BF, Wetterberg L.
Hypothalamic_pituitary_gonadal axis in major depressive
disorders. Acta Psychiatr Scand 1988; 78: 138_46.
94 Seidman SN, Araujo AB, Roose SP, Devanand DP, Xie S, Cooper
TB, et al. Low testosterone levels in elderly men with dysthymic
disorder. Am J Psychiatry 2002; 159: 456_9.
95 Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D.
Bioavailable testosterone and depressed mood in older men: the
Rancho Bernardo Study. J Clin Endocrinol Metab 1999; 84:
573_7.
96 Seidman SN, Araujo AB, Roose SP, McKinlay JB. Testosterone
level, androgen receptor polymorphism, and depressive
symptoms in middle-aged men. Biol Psychiatry 2001; 50: 371_6.
97 Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A
long-term prospective study of the physiologic and behavioural
effects of hormone replacement in untreated hypogonadal men.
J Androl 1992; 13: 297_304.
98 Rabkin JG, Wagner GJ, Rabkin R. A double-blind,
placebo-controlled trial of testosterone therapy for HIV-positive men with
hypogonadal symptoms. Arch Gen Psychiatry 2000; 57: 141_7.
99 Zitzmann M, Nieschlag E. Testosterone levels in healthy men
and the relation to behavioural and physical characteristics: facts
and constructs. Eur J Endocrinol 2001; 144: 183_97.
100 Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic
doses of testosterone on mood and aggression in normal men: a
randomized controlled trial. Arch Gen Psychiatry 2000; 57:
133_40.
101 Christiansen K. Behavioural correlates of testosterone. In:
Nieschlag E, Behre HM, editors. Testosterone: Action Deficiency
Substitution, 2nd edn. Berlin: Springer; 1998: 107_42.
102 Kouri EM, Lukas SE, Pope HG Jr, Oliva PS. Increased aggressive
responding in male volunteers following the administration of
gradually increasing doses of testosterone cypionate. Drug
Alcohol Depend 1995; 40: 73_9.
103 Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N,
Shirazi A, et al. The effects of supraphysiological doses of
testosterone on angry behaviour in healthy eugonadal men _ a
clinical research center study. J Clin Endocrinol Metab 1996; 81:
3754_8.
104 O'Connor DB, Archer J, Hair WM, Wu FC.
Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol
Behav 2002; 75: 557_66.
105 Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow
DA, et al. Effect of testosterone treatment on body composition
and muscle strength in men over 65 years of age. J Clin
Endocrinol Metab 1999; 84: 2647_53.
106 Van Zyl CG, Noakes TD, Lambert MI. Anabolic_androgenic
steroid increases running endurance in rats. Med Sci Sports Exerc
1995; 27: 1385_9.
107 Ekblom B, Holmberg HC, Eriksson K. Doping in endurance
sports. Survey of individual Hb levels can expose doping.
Lakartidningen 2001; 98: 5490_2, 5495_6.
108 Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G.
The effects of testosterone treatment on body composition and
metabolism in middle-aged obese men. Int J Obes Related Metab
Disorders 1992; 16: 991_7.
|